Literature DB >> 17521501

Beta-blocker contraindications: are there patients or situations where use is inappropriate?

S D Naik1, Ronald S Freudenberger.   

Abstract

beta-blockers have been conclusively proven to increase survival and improve symptoms of heart failure, yet there is underutilization of these agents most commonly because of misunderstandings of the relative contraindications and adverse events during treatment. In this manuscript, we discuss the potential contraindications to beta-blockers in heart failure and compare the true risks against the significant benefits.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17521501     DOI： 10.1007/s11897-007-0006-5

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN： 1546-9530


  36 in total

1.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

2.  Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.

Authors:  Shelley R Salpeter; Thomas M Ormiston; Edwin E Salpeter
Journal:  Ann Intern Med       Date:  2002-11-05       Impact factor: 25.391

3.  Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.

Authors:  C W Yancy; M B Fowler; W S Colucci; E M Gilbert; M R Bristow; J N Cohn; M A Lukas; S T Young; M Packer
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

4.  Beta blockade to decrease silent myocardial ischemia during peripheral vascular surgery.

Authors:  P F Pasternack; E A Grossi; F G Baumann; T S Riles; P J Lamparello; G Giangola; L K Primis; R Mintzer; A M Imparato
Journal:  Am J Surg       Date:  1989-08       Impact factor: 2.565

5.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

Authors:  Marcus D Flather; Marcelo C Shibata; Andrew J S Coats; Dirk J Van Veldhuisen; Aleksandr Parkhomenko; Joszef Borbola; Alain Cohen-Solal; Dan Dumitrascu; Roberto Ferrari; Philippe Lechat; Jordi Soler-Soler; Luigi Tavazzi; Lenka Spinarova; Jiri Toman; Michael Böhm; Stefan D Anker; Simon G Thompson; Philip A Poole-Wilson
Journal:  Eur Heart J       Date:  2005-01-09       Impact factor: 29.983

Review 6.  Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.

Authors:  Steven Joseph Haas; Theo Vos; Richard E Gilbert; Henry Krum
Journal:  Am Heart J       Date:  2003-11       Impact factor: 4.749

Review 7.  Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure.

Authors:  Ali Ahmed
Journal:  Eur J Heart Fail       Date:  2003-12       Impact factor: 15.534

8.  Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.

Authors:  Eugene Kotlyar; Anne M Keogh; Peter S Macdonald; Ruth H Arnold; Dermot J McCaffrey; Allan R Glanville
Journal:  J Heart Lung Transplant       Date:  2002-12       Impact factor: 10.247

9.  Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure.

Authors:  Prakash C Deedwania; Stephen Gottlieb; Jalal K Ghali; Finn Waagstein; John C M Wikstrand
Journal:  Eur Heart J       Date:  2004-08       Impact factor: 29.983

10.  Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.

Authors:  Wendy A Gattis; Christopher M O'Connor; Dianne S Gallup; Vic Hasselblad; Mihai Gheorghiade
Journal:  J Am Coll Cardiol       Date:  2004-05-05       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.